Public Release: 

A marker for new blood vessel formation in tumors

PLOS



αvβ3 integrin expression in tumors. (Photo: Roland Haubner, et al.)
Click here for a high resolution photograph.

In a paper in this month's freely-available online global health journal PLoS Medicine, Roland Haubner and colleagues describe how a compound they have developed can be used together with highly sensitive positron emission tomography (PET) scanning to measure the amount of new blood vessel growth in some tumors.

New blood vessel growth - angiogenesis - is important for the growth of tumors; several drugs target angiogenesis specifically. The compound previously developed by Haubner and colleagues is a fluorine-labeled glycopeptide, ([18F]Galacto-RGD), which binds tightly to a receptor - αvβ3 integrin -expressed in some tumors, especially in the blood vessels. As well as a role in angiogenesis, integrins are important in holding tumor cells together and connecting them with the extracellular matrix; what happens when these interactions break down is one of the keys to determining how tumors metastasize.

Haubner and colleagues' work, in a mouse with human melanoma and in a small study of patients with tumors including melanoma, suggests that the marker is truly reflecting the in vivo level of the integrin. Hence the marker could be used to identify tumors that express this marker, assess the degree of new vessel formation in tumors, and help in the planning and monitoring of anti-angiogenic therapies which target this integrin.

###

Citation: Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, et al. (2005) Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2(3): e70.

CONTACT: Roland Haubner
Universitatsklinik fur Nuklearmedizin
Medizinische Universitat Innsbruck
Anichstrasse 35
A-6020 Innsbruck Austria
+43-512-504-80069
+43-512-504-22659 (fax)
Roland.Haubner@uibk.ac.at

PLEASE MENTION PLoS Medicine (www.plosmedicine.org) AS THE SOURCE FOR THESE ARTICLES. THANK YOU.

All works published in PLoS Medicine are open access. Everything is immediately available without cost to anyone, anywhere - to read, download, redistribute, include in databases, and otherwise use - subject only to the condition that the original authorship is properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.

About PLoS Medicine
PLoS Medicine is an open access, freely available international medical journal. It publishes original research that enhances our understanding of human health and disease, together with commentary and analysis of important global health issues. For more information, visit http://www.plosmedicine.org

About the Public Library of Science

The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.